RESULTS 31% of patients had stable coronary artery disease and 68.9% acute coronary syndromes (49.4% Non-STEMI and 19.5% STEMI). 46% of patients were diabetic. 48.3% of lesions were bifurcations, 17.2% diffuse and 52.8% type B2/C. Mean vessel diameter and length were 2.43 AE 0.35 mm and 16.03 AE 5.6 mm, respectively. 77 % of the lesions were treated with PEB, 19.5% with PEB and BMS and 3.4% with PEB and DES. There were no significant differences regarding baseline characteristics of these three groups neither in the MACE rate after a long-term follow-up (p¼0.5). During follow-up, 6 patients died (1 cardiovascular and 5 non-cardiovascular deaths) and a TLR rate of 2.3% was observed. Two cases of non-fatal myocardial infarction (2.3%) and no cases of thrombosis were observed, immediately after the procedure nor during follow-up. 16.1% of patients had angiographic follow-up. We did not observe a higher need for additional stent after PEB in complex lesions such as diffuse lesions (p¼0.7) and bifurcations (p¼0.7). However a higher MACE rate at 5 years was observed in bifurcations and ostial lesions.
CONCLUSIONS Percutaneous interventions of "De Novo" coronary lesions with Sequent Please Ò PEB offers very favorable results at a very long-term follow up. There was not a higher need for additional stent in cases of diffuse and bifurcated lesions. BACKGROUND Drug eluting balloons currently constitute one of the therapeutic tools used in percutaneous coronary intervention (PCI) of both stent restenosis and "De Novo" coronary lesions, mainly in bifurcations and small vessels. Diabetic patients represent an unfavorable subgroup because of their higher restenosis and adverse events rates. Nowadays, the results at a very long-term follow up are unclear in this subset of patients. The main objective of this study was to evaluate the efficacy and safety of second-generation Sequent Please Ò paclitaxel eluting balloon (PEB) at 6 years in diabetics.
METHODS
We prospectively included 111 consecutive diabetic patients (69AE12 years, 64% male) with 111 lesions (de novo or restenosis) treated with PEB between March 2009 and January 2014. We evaluated the presence of major cardiac events (MACE) after a prolonged clinical follow-up (median 47 months): death, nonfatal myocardial infarction, target lesion revascularization (TLR) and thrombosis.
RESULTS 44.2% of patients had stable coronary artery disease and 55.8% acute coronary syndromes (45% Non-STEMI and 10.8% STEMI). 20.7% of lesions were bifurcations. Of the 111 lesions, 36.1% were "De Novo" lesions and 63.9% restenosis [37.8% restenosis of bare metal stent (BMS) and 26.1% of drug-eluting stents (DES)]. 88.3% of the lesions were treated with PEB, 8.1% with PEB and BMS and 3.6% with PEB and DES. There were no significant differences regarding baseline characteristics of these three groups neither in the MACE rate after a long-term follow-up (p¼0.8). During follow-up, 9 patients died (3 cardiovascular and 6 non-cardiovascular deaths), and a TLR rate of 3.6% and two non-fatal myocardial infarction rate of 1.8% were observed. No cases of thrombosis were observed, immediately after the procedure nor during follow-up. 19.8% of patients had an angiographic follow-up. Bifurcated lesions presented a higher rate of dissection after PEB (p¼0.016) and a higher need of additional stent (p¼0.025).
CONCLUSIONS In diabetic patients, percutaneous coronary intervention of de novo coronary lesions and in-stent restenosis (both of BMS and DES) with Sequent Please Ò PEB provide very favorable results at a very long-term follow up. Bifurcated lesions presented a higher rate of dissection after PEB and a higher need of additional stent.
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First report on the angiographic and OCT findings of combining paclitaxel coated balloon with an everolimus eluting stent in a porcine model Paul Ong, 1 Agnes S. Seah, 2 Philip Wong 3 1 Tan Tock Seng Hospital, Singapore, Singapore; 2 BBraun Singapore, Singapore, Singapore; 3 Innoheart, Singapore, Singapore BACKGROUND There has been much interest in the use of paclitaxel coated balloon (PCB) only angioplasty in de novo coronary lesions. In certain clinical situations such as bifurcation, recoil or major dissection after PCB deployment an additional stent may be implanted to support vessel patency. The consensus opinion is to use a bare metal stent (BMS) instead of a drug eluting stent to cover the PCB treated segment. This may avoid the unknown effect of combining paclitaxel with a limus agent. We designed a porcine model to compare the angiographic and optical coherence tomography (OCT) findings of implanting an everolimus eluting stent (EES) in the same segment of the coronary artery pre-treated with a PCB (paccocath as carrier) with EES alone and PCB plus BMS.
METHODS 7 female swine averaging 46.0AE2.4 kg were studied. Under general anesthetic, the 3 coronary arteries of each animal were randomly implanted with 1. PCB (3.0 by 15mm) followed by EES (3.0 by 8mm); 2. PCB (3.0 by 15mm) followed by BMS (3.0 by 8mm) and 3. EES (3.0 by 8mm) alone. Quantitative coronary angiography (QCA) and OCT were carried out post implantation. QCA and OCT were repeated after 28AE1 days.
RESULTS
All arteries remained patent and demonstrated no sign of thrombus formation on angiogram or OCT. The was no difference in lumen loss at 1 month between the 3 treatment groups (0.52AE0.36mm, 0.45AE0.44mm and 0.30AE0.24mm for EES, PCBþEES and PCBþBMS respectively, p¼0.54). There was no difference in diameter stenosis at 1 month (8.71AE11.88%, 4.14AE12.97% and 4.80AE7.65% for EES, PCBþEES and PCBþBMS respectively, p¼0.71). The mean endothelial area measured by OCT at 1 month were 1.58AE0.83mm2, 0.95AE0.19mm2 and 0.97AE0.23mm2 for EES, PCBþEES and PCBþBMS respectively, p¼0.064.
CONCLUSIONS The combination of PCB with EES appeared to be safe and effective compared to EES alone. There is a trend to suggest the combination of PCB with EES may be more effective in suppressing neointimal hyperplasia than using EES as observed in the lower endothelial area measurement. Using EES to bail out suboptimal PCB therapy appeared to be safe and effective in the porcine model. Further histological analysis and larger cohort may provide more information on this treatment strategy.
